Cargando…

Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis

IMPORTANCE: Combinations of chemotherapy with immunotherapy or bevacizumab in first-line treatments of extensive-stage small cell lung cancer (ES-SCLC) have been evaluated in various clinical trials. However, it remains unclear what the optimal combination regimen is. OBJECTIVE: To clarify which fir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ting, Zhang, Zhonghan, Luo, Fan, Zhao, Yuanyuan, Hou, Xue, Liu, Tingting, Wang, Kai, Zhao, Hongyun, Huang, Yan, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573680/ https://www.ncbi.nlm.nih.gov/pubmed/33074323 http://dx.doi.org/10.1001/jamanetworkopen.2020.15748

Ejemplares similares

Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer
por: Zhou, Ting, et al.
Publicado: (2020)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients
por: Liu, Tingting, et al.
Publicado: (2021)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2023)

Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2018)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
por: Lin, Guo, et al.
Publicado: (2023)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non–Small Cell Lung Cancer Treated With First-Line Therapy
por: Ma, Xinran, et al.
Publicado: (2022)

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
por: Huang, Chengliang, et al.
Publicado: (2020)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Comparison of the Prognostic Value of Systemic Inflammation Response Markers in Small Cell Lung Cancer Patients
por: Zhou, Ting, et al.
Publicado: (2019)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment
por: Zhou, Ting, et al.
Publicado: (2015)

The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer
por: Zhou, Ning-ning, et al.
Publicado: (2018)

Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
por: Liu, Chang, et al.
Publicado: (2022)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

The First Scube3 Mutant Mouse Line with Pleiotropic Phenotypic Alterations
por: Fuchs, Helmut, et al.
Publicado: (2016)

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
por: Ortega-Franco, A., et al.
Publicado: (2021)

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)
por: Zhou, Ting, et al.
Publicado: (2017)

A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer
por: Luo, Hao, et al.
Publicado: (2019)

Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
por: Haro, Greg J., et al.
Publicado: (2019)

“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
por: Wang, Mingqi, et al.
Publicado: (2021)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

On the use of GBLUP and its extension for GWAS with additive and epistatic effects
por: Zhang, Jie, et al.
Publicado: (2021)

Meta‐analysis of PD‐(L)1 inhibitor plus chemotherapy versus chemotherapy as first‐line treatment in extensive‐stage small‐cell lung cancer
por: Lu, Jiangyue, et al.
Publicado: (2023)

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
por: Wang, Jie, et al.
Publicado: (2021)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
por: Hotta, Katsuyuki, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022)

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
por: Kim, Soo Han, et al.
Publicado: (2023)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6no8754n2orjj7b550bhbbjbo3